Aliases & Classifications for Arteriosclerosis

MalaCards integrated aliases for Arteriosclerosis:

Name: Arteriosclerosis 12 55 6 44 15 17 72
Arteriosclerotic Vascular Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2349
MeSH 44 D001161
NCIt 50 C34398
SNOMED-CT 68 28960008 72092001
ICD10 33 I70
UMLS 72 C0003850

Summaries for Arteriosclerosis

Disease Ontology : 12 An artery disease that is characterized by a thickening and hardening of arterial walls in the arteries.

MalaCards based summary : Arteriosclerosis, also known as arteriosclerotic vascular disease, is related to arteriosclerosis obliterans and pseudoxanthoma elasticum, and has symptoms including angina pectoris An important gene associated with Arteriosclerosis is HS3ST1 (Heparan Sulfate-Glucosamine 3-Sulfotransferase 1), and among its related pathways/superpathways are Degradation of the extracellular matrix and G-protein signaling Regulation of p38 and JNK signaling mediated by G-proteins. The drugs Pravastatin and Methyltestosterone have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and kidney, and related phenotypes are Decreased free cholesterol and cardiovascular system

Wikipedia : 75 Arteriosclerosis is the thickening, hardening, and loss of elasticity of the walls of arteries. This... more...

Related Diseases for Arteriosclerosis

Diseases in the Arteriosclerosis family:

Arteriosclerosis, Severe Juvenile

Diseases related to Arteriosclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 477)
# Related Disease Score Top Affiliating Genes
1 arteriosclerosis obliterans 35.2 VCAM1 ICAM1 ADIPOQ
2 pseudoxanthoma elasticum 33.0 SPP1 MGP ELN
3 hyperlipoproteinemia, type iii 32.7 HMGCR COG2 APOE APOB APOA1
4 coronary artery anomaly 32.5 SERPINE1 PON1 HMGCR EDN1 CRP COG2
5 coronary heart disease 1 32.0 SERPINE1 PON1 HS3ST1 HMGCR CRP COG2
6 atherosclerosis susceptibility 31.8 VCAM1 SERPINE1 PPARG PON1 ICAM1 CRP
7 peripheral vascular disease 31.6 VCAM1 SERPINE1 CRP APOB APOA1
8 hypertriglyceridemia, familial 31.5 APOE APOB APOA1
9 hypertension, essential 31.3 SERPINE1 EDN1 APOB APOA1 ADIPOQ
10 ischemia 31.2 PON1 ICAM1 HMOX1 EDN1
11 vasculitis 31.2 VCAM1 ICAM1 CRP CCL2
12 takayasu arteritis 31.2 VCAM1 PON1 CRP
13 carotid stenosis 31.1 SPP1 CRP APOE
14 peripheral artery disease 31.1 VCAM1 CRP CCL2 APOB
15 aortic aneurysm, familial abdominal, 1 31.1 ELN CCL2 APOE
16 aortic atherosclerosis 30.9 SPP1 PON1 APOE
17 glucose intolerance 30.8 PPARG CRP APOB ADIPOQ
18 coronary artery aneurysm 30.8 VCAM1 CCL2 ADIPOQ
19 cerebral aneurysms 30.7 ELN CCL2
20 apnea, obstructive sleep 30.7 EDN1 CRP ADIPOQ
21 endocarditis 30.7 VCAM1 HSPD1 CRP
22 chronic venous insufficiency 30.7 VCAM1 SERPINE1 ICAM1
23 connective tissue disease 30.7 SPP1 HSPD1 ELN EDN1
24 coronary stenosis 30.7 SERPINE1 PON1 ICAM1 CRP APOE APOB
25 cerebrovascular disease 30.6 VCAM1 SERPINE1 PON1 ICAM1 CRP APOE
26 venous insufficiency 30.6 VCAM1 SERPINE1 ICAM1 CRP
27 acute myocardial infarction 30.6 SERPINE1 EDN1 CRP APOB APOA1
28 peritonitis 30.5 ICAM1 CRP CCL2
29 generalized atherosclerosis 30.5 CRP APOE
30 proteasome-associated autoinflammatory syndrome 1 30.5 VCAM1 PPARG ICAM1 CRP CCL2 ADIPOQ
31 lymphocytic vasculitis 30.4 VCAM1 ICAM1
32 pulmonary disease, chronic obstructive 30.4 HMOX1 ELN CRP CCL2
33 homozygous familial hypercholesterolemia 30.4 HMGCR APOE APOB
34 sleep apnea 30.4 ICAM1 EDN1 CRP APOE ADIPOQ
35 pulmonary edema 30.4 ICAM1 HMOX1 EDN1 CRP
36 xanthomatosis 30.4 HMGCR APOE APOB
37 tangier disease 30.3 APOE APOB APOA1
38 kawasaki disease 30.3 HSPD1 CRP CCL2
39 arcus corneae 30.3 COG2 APOE APOB APOA1
40 heart disease 30.3 SERPINE1 PON1 ICAM1 ELN EDN1 CRP
41 lipid metabolism disorder 30.3 SERPINE1 PPARG HMGCR CRP COG2 APOE
42 lung disease 30.2 HMOX1 ELN EDN1 CCL2
43 prediabetes syndrome 30.2 PPARG CRP COG2 APOB ADIPOQ
44 carotid artery disease 30.2 CRP COG2 CCL2 APOE APOB APOA1
45 diabetes mellitus 30.2 SERPINE1 PPARG PON1 HSPD1 HMGCR EDN1
46 stroke, ischemic 30.1 SERPINE1 PON1 HMGCR CRP COG2 APOE
47 macular degeneration, age-related, 1 30.1 HMOX1 CRP CCL2 APOE APOB
48 kidney disease 29.9 SPP1 SERPINE1 MGP HMOX1 HMGCR EDN1
49 overnutrition 29.9 SERPINE1 PPARG CRP COG2 CCL2 APOB
50 body mass index quantitative trait locus 11 29.7 SERPINE1 PPARG PON1 HMOX1 CRP COG2

Graphical network of the top 20 diseases related to Arteriosclerosis:



Diseases related to Arteriosclerosis

Symptoms & Phenotypes for Arteriosclerosis

UMLS symptoms related to Arteriosclerosis:


angina pectoris

GenomeRNAi Phenotypes related to Arteriosclerosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 8.92 APOA1 APOB APOE HMGCR

MGI Mouse Phenotypes related to Arteriosclerosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.3 ADIPOQ APOA1 APOB APOE CRP EDN1
2 homeostasis/metabolism MP:0005376 10.3 ADIPOQ APOA1 APOB APOE COG2 CRP
3 growth/size/body region MP:0005378 10.28 ADIPOQ APOB APOE COG2 EDN1 HMGCR
4 cellular MP:0005384 10.17 ADIPOQ APOA1 APOB APOE HMOX1 HSPD1
5 immune system MP:0005387 10.06 ADIPOQ APOB APOE CCL2 CRP HMOX1
6 mortality/aging MP:0010768 10 ADIPOQ APOB APOE EDN1 HMGCR HMOX1
7 liver/biliary system MP:0005370 9.91 ADIPOQ APOA1 APOB APOE HMGCR HMOX1
8 muscle MP:0005369 9.65 ADIPOQ APOB APOE EDN1 HMOX1 HSPD1
9 renal/urinary system MP:0005367 9.23 ADIPOQ APOE EDN1 HMOX1 MGP PPARG

Drugs & Therapeutics for Arteriosclerosis

Drugs for Arteriosclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 309)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pravastatin Approved Phase 4 81093-37-0 54687
2
Methyltestosterone Approved Phase 4 58-18-4 6010
3
Testosterone enanthate Approved Phase 4 315-37-7 9416
4
Testosterone Approved, Experimental, Investigational Phase 4 481-30-1, 58-22-0 6013 10204
5
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
6
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
7
Remifentanil Approved Phase 4 132875-61-7 60815
8
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
9
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
10
Atorvastatin Approved Phase 4 134523-00-5 60823
11
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
12
Dipyridamole Approved Phase 4 58-32-2 3108
13
Acetaminophen Approved Phase 4 103-90-2 1983
14
Metformin Approved Phase 4 657-24-9 4091 14219
15
Insulin Detemir Approved Phase 4 169148-63-4 5311023
16
Zinc Approved, Investigational Phase 4 7440-66-6 32051
17
Insulin Aspart Approved Phase 4 116094-23-6 16132418
18
Ezetimibe Approved Phase 4 163222-33-1 150311
19
Fenofibrate Approved Phase 4 49562-28-9 3339
20
Simvastatin Approved Phase 4 79902-63-9 54454
21
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
22
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
23
Propranolol Approved, Investigational Phase 4 525-66-6 4946
24
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
25
Atenolol Approved Phase 4 29122-68-7 2249
26
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
27
Sevelamer Approved Phase 4 52757-95-6
28
Calcium acetate Approved, Investigational Phase 4 62-54-4
29
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
30
Liraglutide Approved Phase 4 204656-20-2 44147092
31
Amlodipine Approved Phase 4 88150-42-9 2162
32
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
33
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
34
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
35
Probucol Approved, Investigational Phase 4 23288-49-5 4912
36
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
37
tannic acid Approved Phase 4 1401-55-4
38
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
39
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
40
Chlorthalidone Approved Phase 4 77-36-1 2732
41
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
42
Epoprostenol Approved Phase 4 35121-78-9, 61849-14-7 5282411 5280427
43
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
44
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616 46835353
45
Mycophenolic acid Approved Phase 4 24280-93-1 446541
46
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
47
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
48
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
49
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
50
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795

Interventional clinical trials:

(show top 50) (show all 429)
# Name Status NCT ID Phase Drugs
1 Evaluation of Antiplatelet Therapy in Lower Limb Endovascular Treatment Unknown status NCT00912756 Phase 4 cilostazol
2 Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) Unknown status NCT01777503 Phase 4 prasugrel;Clopidogrel
3 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis - High-Resolution Magnetic Resonance Imaging Study (STAMINA-MRI Study) Unknown status NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
4 Randomized Trial of Paclitaxel Eluting Balloon or Conventional Balloon for Treatment of In-Stent Restenosis of the Superficial Femoral Artery in Patients With Symptomatic Peripheral Artery Disease (ISAR-PEBIS) Unknown status NCT01083394 Phase 4
5 Randomized Trial of Stenting After Dilation With or Without Paclitaxel Eluting Balloon or Atherectomy in Patients With Symptomatic Peripheral Artery Disease Unknown status NCT00986752 Phase 4
6 Phase 3 Study of Atorvastatin Effects on Carotid Atherosclerosis Unknown status NCT00640744 Phase 4 Atorvastatin
7 A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
8 Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A Prospective, Randomised Trial of Sirolimus Versus Cyclosporine.(Fibrasic) Unknown status NCT00493194 Phase 4 sirolimus;cyclosporine;daclizumab
9 The Effect of Testosterone Therapy on Angina Threshold and Atheroma in Patients With Chronic Stable Angina Unknown status NCT00131183 Phase 4 Nebido
10 The Effects of Pravastatin and Rosuvastatin on the Tissue Characteristics and Morphology of Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
11 Influence of Vitamin K2 Administration on Vessel Calcification Markers in Patients With Chronic Kidney Disease Unknown status NCT01101698 Phase 4 Vitamin K2+10μg cholecalciferol;Vitamin D
12 The Low HDL On Six Weeks Statin Therapy (LOW) Study Unknown status NCT00238004 Phase 4 Nicotinic acid
13 Comparison of Intravenous Anesthetics and Volatile Anesthetics on Postoperative Cognitive Dysfunction of Patients Undergoing Endovascular Repair of Aortic Aneurysm and Endovascular Treatment of Arteriosclerosis Obliterans of Lower Extremities. Completed NCT02107170 Phase 4 Sevoflurane;Propofol;Remifentanil
14 Effects of Celecoxib on Restenosis After Percutaneous Coronary Intervention and Evolution of Atherosclerosis (COREA) Trial Completed NCT00292721 Phase 4 Celecoxib
15 A Prospective, Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Atorvastatin Versus Pravastatin on the Progression and Quantification of Coronary Atherosclerotic Lesions as Measured by Intravascular Ultrasound (REVERSAL) Completed NCT00380939 Phase 4 Atorvastatin;Pravastatin
16 A Randomized, Control,Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker Completed NCT00823849 Phase 4 Cilostazol;Probucol;Cilostazol+Probucol
17 A Randomised, Crossover Study Comparing the Biochemical and Platelet Effects of Modified-release Dipyridamole/Aspirin (200mg/25 mg bd; Asasantin Retard®) With Aspirin (75 mg qd) in Coronary Artery Disease Patients With Aspirin Resistance Manifesting as Persistent Thromboxane Formation. Completed NCT00129038 Phase 4 modified-release dipyridamole/aspirin;aspirin
18 A Multicenter, Randomized Double-Blind Study Comparing The Pleiotropic Effects Of Atorvastatin 10 Mg And 80 Mg Over A 26-Week Period In Subjects With Coronary Atherosclerosis Completed NCT00163202 Phase 4 Atorvastatin
19 The Ontario Multidetector Computed Tomography (MDCT) Coronary Angiography Study (OMCAS) Completed NCT00371891 Phase 4
20 A Prospective, Randomized, Multicenter Comparison of the Drug-Eluting Stent Systems YUKON Choice and TAXUS Liberté in Patients With Diabetes Mellitus Completed NCT00368953 Phase 4
21 Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery Completed NCT01334866 Phase 4
22 ACTFAST: Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration. A Multicenter, Twelve-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, 40 Mg, And 80 Mg Completed NCT00442845 Phase 4 Atorvastatin (Lipitor)
23 ACTFAST (2): Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration: A Multicenter, Twelve-Week Treatment, Single-Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 mg, 20 mg, 40 mg, And 80 mg. Completed NCT00442325 Phase 4 Atorvastatin (Lipitor)
24 Prospective, Randomized Trial of Drug-eluting Stents vs. Bare Metal Stents for the Reduction of Restenosis in Bypass Grafts. Completed NCT00611910 Phase 4
25 Paracetamol and Endothelial Function in Patients With Stable Coronary Artery Disease Completed NCT00534651 Phase 4 Paracetamol
26 The Effect of Metformin Versus Placebo, Including Three Insulin-Analogue Regimens With Variating Postprandial Glucose Regulation, on CIMT in T2DM Patients - A Randomized, Multicenter Trial Completed NCT00657943 Phase 4 metformin;insulin detemir;insulin aspart + insulin aspart protamin;Insulin aspart
27 A Single Center, Randomized, Open Label, Multiple Dose, Crossover Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients With Stable Coronary Artery Disease Completed NCT01706510 Phase 4 Ticagrelor;Clopidogrel
28 A Single Center, Randomized, Parallel Groups, Placebo-Controlled Study Comparing The Efficacy, Safety, And Tolerability Of The Daily Co-administration Of Ezetimibe 10 Mg Or Ezetimibe Placebo To Ongoing Treatment With Atorvastatin 10 Mg In Subjects With Primary Hypercholesterolemia And Multiple Coronary Heart Disease Risk Factors in Indonesian Population. Completed NCT00319449 Phase 4 Ezetimibe;Placebo;Atorvastatin 10 mg
29 A Randomized, Control, Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject Completed NCT00823875 Phase 4 Cilostazol group;Probucol group;Cilostazol + Probucol group;control group
30 Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial Completed NCT02510547 Phase 4
31 Pilot Study: Inflammation and Coronary Artery Disease. Role of AT1 Receptor Antagonism Completed NCT00274144 Phase 4 telmisartan 40 mg;placebo 40 mg
32 Pharmacogenomics of Antiplatelet Response - II Completed NCT01894555 Phase 4 Aspirin
33 Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Completed NCT00110448 Phase 4 Aspirin;No aspirin
34 Prospective, Randomized, Comparative Study to Evaluate the Effect of Iodixanol 320 Compared to Iomeprol 350 on Contrast Medium Induced Nephropathy in Patients With Impaired Renal Function Undergoing PCI Completed NCT00390585 Phase 4 Iodixanol 320;Iomeprol 350
35 Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients: A Prospective Multicenter Registry (OPERA) Completed NCT01325935 Phase 4 Clopidogrel
36 Reducing Total Cardiovascular Risk in an Urban Community Completed NCT00241904 Phase 4 Antiplatelet Agents;Beta Blocker;ACE Inhibitors
37 Influence of Sirolimus and MMF on Vascular Function and Markers of Cellular Function in Renal Transplant Recipients - Positive Effects of Calcineurin-free Immunosuppression Completed NCT00204321 Phase 4 sirolimus (drug), mmf (drug)
38 Qualitative and Quantitative Characterization of HDL in T2D After Fenofibrate or Niacin Treatment in Spanish Population Completed NCT02153879 Phase 4 Fenofibrate;Niacin plus laropiprant
39 Omacor; Omega-3-Acid Ethyl Ester 90 (n-3 PUFA) and Risk Factors in HIV Infected Patients Treated With HAART, With Special Focus on Lipids Completed NCT00296153 Phase 4 Omega-3-acid ethyl esters 90
40 Effect of the Angiotensin II Receptor Antagonist Irbesartan on Insulin Sensitivity and Metabolic Profile in Patients With Chronic Heart Failure Completed NCT00347087 Phase 4 Irbesartan
41 ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial Completed NCT00161070 Phase 4 anticoagulation;aspirin and dipyridamole;aspirin alone
42 A Pilot Study to Determine the Effect of Celecoxib on Markers of Inflammation in Patients With Hypertension and Coronary Artery Disease Completed NCT00471341 Phase 4 Celecoxib;placebo
43 The Effect Of Ezetimibe In Addition To Optimal Cholesterol-Lowering Statin Therapy On The Plaque Composition In Patients With Acute Myocardial Infarction - Assessed By Optical Coherence Tomography And Intravascular Ultrasound. Completed NCT01385631 Phase 4 Ezetimibe;Placebo
44 A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions Completed NCT01182428 Phase 4
45 CARE-2 (Calcium Acetate (PhosLo®)/Sevelamer(Renagel®) Evaluation Study 2) Completed NCT00211939 Phase 4 calcium acetate;sevelamer;atorvastatin
46 Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practising in a Team Environment (COLLABORATE) Completed NCT00351676 Phase 4 Optimizing therapeutic treatments
47 Randomised Controlled Trial of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease: A Pilot Study Completed NCT00395382 Phase 4 Alendronate;Placebo
48 A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions Completed NCT00496938 Phase 4
49 Preprocedural Asprin Reload for Native Coronary Disease Treated by Angioplasty: Reperfusion Indexes Evaluation and Improvement of Clinical Outcome -PANTAREI Study Completed NCT01374698 Phase 4 Aspirin
50 Liraglutide in Type 1 Diabetes. A Randomised, Double-blind, Placebo Controlled Study of the Effect of Liraglutide as an Additional Treatment to Insulin on HbA1c, Body Weight and Hypoglycaemia in Poorly Regulated Type 1 Diabetes Patients Completed NCT01612468 Phase 4 Liraglutide;Placebo

Search NIH Clinical Center for Arteriosclerosis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Epoprostenol
Epoprostenol Sodium
Isoxsuprine
Isoxsuprine Hydrochloride

Cochrane evidence based reviews: arteriosclerosis

Genetic Tests for Arteriosclerosis

Anatomical Context for Arteriosclerosis

MalaCards organs/tissues related to Arteriosclerosis:

41
Heart, Endothelial, Kidney, Smooth Muscle, Brain, Testes, Bone

Publications for Arteriosclerosis

Articles related to Arteriosclerosis:

(show top 50) (show all 11534)
# Title Authors PMID Year
1
Decrease in glomerular filtration rate by plasma low-density lipoprotein cholesterol in subjects with normal kidney function assessed by urinalysis and plasma creatinine. 9 38
20097344 2010
2
Aldosterone antisecretagogue and antihypertensive actions of adrenomedullin in patients with primary aldosteronism. 9 38
20150911 2010
3
Paraoxonase-1 gene haplotypes are associated with metabolic disturbances, atherosclerosis, and immunologic outcome in HIV-infected patients. 9 38
20078196 2010
4
Wild-type apo A-I and apo A-I(Milano) gene transfer reduce native and transplant arteriosclerosis to a similar extent. 9 38
19066833 2009
5
Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells. 9 38
19132220 2008
6
Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome. 9 38
18464944 2008
7
Influence of serum high-molecular-weight and total adiponectin on arteriosclerosis in IgA nephropathy patients. 9 38
18332637 2008
8
Analysis of plasma adipocytokines related to clinical and laboratory data in the maintenance hemodialysis patients. 9 38
18670142 2008
9
[Endothelin-1 production and its involvement in cardiovascular diseases]. 9 38
17827914 2007
10
[Pioglitazone protects against elastocalcinosis and improves aortic wall elasticity]. 9 38
17489075 2007
11
General anesthesia and methylenetetrahydrofolate reductase deficiency. 9 38
18008117 2007
12
[Effects of recombinant adenovirus encoding human apM1 gene on proliferation and nitric oxide synthase activity in human umbilical vein endothelial cells]. 9 38
17274908 2006
13
Upregulation of proteinase-activated receptors and hypercontractile responses precede development of arterial lesions after balloon injury. 9 38
16844909 2006
14
Endothelial-mediated regulation of cerebral microcirculation. 9 38
17244945 2006
15
Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. 9 38
16616959 2006
16
TGF-beta1 generates a specific multicomponent extracellular matrix in human coronary SMC. 9 38
16796604 2006
17
Protective genes in the vessel wall: Modulators of graft survival and function. 9 38
16829794 2006
18
Signaling and functions of angiopoietin-1 in vascular protection. 9 38
16645151 2006
19
Recent advances in the relationship between obesity, inflammation, and insulin resistance. 9 38
16613757 2006
20
[Effects of active components extracted from Qixue Bingzhi Recipe on proliferation of vascular smooth muscle cells and expressions of platelet-derived growth factor and its receptor genes]. 9 38
16409966 2006
21
Adrenomedullin: a protective factor for blood vessels. 9 38
16141406 2005
22
Tempol attenuates the development of hypertensive renal injury in Dahl salt-sensitive rats. 9 38
15882555 2005
23
Matrix Gla protein and osteopontin genetic associations with coronary artery calcification and bone density: the CARDIA study. 9 38
15744522 2005
24
Endothelial nitric oxide synthase gene transfer restores endothelium-dependent relaxations and attenuates lesion formation in carotid arteries in apolipoprotein E-deficient mice. 9 38
15578196 2005
25
Increased plasma lipid-poor apolipoprotein A-I in patients with coronary artery disease. 9 38
15550473 2005
26
[Endothelin-1 and arteriosclerosis]. 9 38
15506470 2004
27
CD14 C(-260)T gene polymorphism, circulating soluble CD14 levels and arteriosclerosis. 9 38
15257175 2004
28
Eukaryotic expression vector of heme oxygenase-1 and its expression in endothelial cell. 9 38
15313669 2004
29
[The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis]. 9 38
15225502 2004
30
Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. 9 38
15181084 2004
31
Inhibition of accelerated graft arteriosclerosis by gene transfer of soluble fibroblast growth factor receptor-1 in rat aortic transplants. 9 38
15072997 2004
32
Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. 9 38
14963043 2004
33
A microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with increased bilirubin and HDL levels but not with coronary artery disease. 9 38
14691581 2004
34
Attenuation of aortic graft arteriosclerosis by systemic administration of Allotrap peptide RDP58. 9 38
12942166 2003
35
[Neurological aspects in antiphospholipid syndrome]. 9 38
15152454 2003
36
Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. 9 38
14581407 2003
37
Effect of low-density lipoprotein apheresis on plasma endothelin-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans. 9 38
14583180 2003
38
[Regulatory effect of yishou tiaozhi tablet on lipids in patients with primary hyperlipidemia]. 9 38
12764909 2003
39
Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. 9 38
12628953 2003
40
Mouse endothelial CD40 expression does not play a role during the development of transplant arteriosclerosis. 9 38
12791519 2003
41
The concentration of lipids, lipoproteins and apolipoproteins in cord blood serum of newborns in the course of intrauterine period. 9 38
15323161 2003
42
Antiinflammatory and antiarteriosclerotic effects of pioglitazone. 9 38
12411463 2002
43
Upregulation of PAI-1 is mediated through TGF-beta/Smad pathway in transplant arteriopathy. 9 38
12231371 2002
44
Hepatocyte growth factor and 24-hour ambulatory blood pressure monitoring. 9 38
12452315 2002
45
Levels of haemostatic factors, arteriosclerosis and cardiovascular disease. 9 38
12616975 2002
46
Gene therapy targeting monocyte chemoattractant protein-1 for vascular disease. 9 38
12560586 2002
47
A survey of the dietary nutritional composition of centenarians. 9 38
11677774 2001
48
[Effect of lower androgen levels on arteriosclerosis]. 9 38
11769606 2001
49
Chromosomal location, exon structure, and vascular expression patterns of the human PDGFC and PDGFD genes. 9 38
11342471 2001
50
Metabolism of hepatocyte growth factor in the heart in patients with coronary artery disease: implication for coronary arteriosclerosis. 9 38
11669408 2001

Variations for Arteriosclerosis

ClinVar genetic disease variations for Arteriosclerosis:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 HS3ST1 NM_005114.3(HS3ST1): c.-108-6848A> G single nucleotide variant risk factor rs16881446 4:11408585-11408585 4:11406961-11406961

Expression for Arteriosclerosis

Search GEO for disease gene expression data for Arteriosclerosis.

Pathways for Arteriosclerosis

Pathways related to Arteriosclerosis according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.58 VCAM1 SPP1 SERPINE1 ICAM1 ELN
2
Show member pathways
12.05 VCAM1 SPP1 ICAM1 ELN CCL2
3
Show member pathways
11.81 HMGCR APOE APOB APOA1
4 11.8 VCAM1 ICAM1 HMOX1 EDN1 CCL2
5 11.77 SERPINE1 HMOX1 EDN1
6
Show member pathways
11.76 APOE APOB APOA1
7 11.76 VCAM1 ICAM1 HMOX1 CCL2
8 11.72 VCAM1 ICAM1 EDN1 CCL2
9 11.59 PPARG APOA1 ADIPOQ
10 11.55 VCAM1 SERPINE1 ICAM1 EDN1 CCL2
11 11.5 SERPINE1 HMOX1 EDN1
12
Show member pathways
11.5 SERPINE1 ICAM1 CRP CCL2 APOE APOB
13 11.36 VCAM1 ICAM1 CCL2
14 11.22 VCAM1 ICAM1 APOA1
15 11.16 MGP HMOX1 CCL2
16 11.15 SPP1 HMOX1 ELN EDN1 CCL2
17 10.7 VCAM1 ICAM1 CCL2

GO Terms for Arteriosclerosis

Cellular components related to Arteriosclerosis according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 intracellular membrane-bounded organelle GO:0043231 9.93 PPARG PON1 HMOX1 HMGCR APOB
2 early endosome GO:0005769 9.89 VCAM1 HSPD1 APOE APOB APOA1
3 endoplasmic reticulum lumen GO:0005788 9.85 SPP1 APOE APOB APOA1
4 high-density lipoprotein particle GO:0034364 9.63 PON1 APOE APOA1
5 very-low-density lipoprotein particle GO:0034361 9.61 APOE APOB APOA1
6 endocytic vesicle lumen GO:0071682 9.58 APOE APOB APOA1
7 low-density lipoprotein particle GO:0034362 9.54 APOE APOB APOA1
8 spherical high-density lipoprotein particle GO:0034366 9.52 PON1 APOA1
9 discoidal high-density lipoprotein particle GO:0034365 9.51 APOE APOA1
10 chylomicron GO:0042627 9.5 APOE APOB APOA1
11 collagen-containing extracellular matrix GO:0062023 9.5 SERPINE1 MGP ICAM1 ELN APOE APOA1
12 extracellular space GO:0005615 9.47 VCAM1 SPP1 SERPINE1 PON1 ICAM1 HSPD1
13 intermediate-density lipoprotein particle GO:0034363 9.33 APOE APOB APOA1
14 extracellular exosome GO:0070062 10.18 VCAM1 SPP1 SERPINE1 PON1 MGP ICAM1
15 extracellular region GO:0005576 10.03 SPP1 SERPINE1 PON1 MGP ELN EDN1

Biological processes related to Arteriosclerosis according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Name GO ID